Biocon witnessed a bullish trading session on Tuesday, with shares climbing more than 6% amidst reports of a significant institutional exit. Mylan, a subsidiary of Viatris, initiated the sale of its 5.64% holding in the Indian drug manufacturing firm.
The divestment, valued at approximately Rs 3,481 crore, involved the exchange of nearly nine crore shares during early market hours. This move marks the conclusion of Mylan's long-standing equity participation in the company.
Market analysts noted that the transaction was executed via block deals at a floor price set at a discount to the previous session's closing levels. Despite the discounted entry point for institutional buyers, the market responded positively to the finality of the exit.
Investors are viewing the clean exit as a potential catalyst for stability, as the overhang of a major stakeholder offloading shares is finally removed from Biocon's capital structure.
